The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Bayer has finalized an agreement to acquire Perfuse Therapeutics for $2.45 billion, a move the company stated is specifically intended to complement and strengthen its existing ophthalmology pipeline. The deal grants Bayer full global rights to the PER-001 program, a specialized asset targeting Glaucoma and Diabetic Retinopathy currently in Phase II clinical development. As an endothelin receptor antagonist, PER-001 is designed to improve vascular blood flow in the eye, representing a significant technological addition to Bayer's portfolio. This acquisition underscores Bayer's commitment to high-margin medical fields and the development of next-generation treatments for vision loss. Industry experts view the integration of this asset as a key driver for long-term growth in the biopharmaceutical sector. The transaction remains subject to standard regulatory approvals and closing conditions.
Sign in to access this content
Sign In